Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
The European Commission has approved Vertex’s Kalydeco (ivacaftor) for the treatment of children and adolescents with cystic fibrosis (CF) who carry the R117H mutation in the cystic fibrosis transmembrane ... Read more
Children with cystic fibrosis (CF) have an altered intestinal virome, or viral communities, compared to healthy children that may impact growth and intestinal inflammation, a case-control study reported. The ... Read more
Kalydeco treatment led to fewer deaths, transplants, hospitalizations, and exacerbations in people with cystic fibrosis (CF) compared to patients who did not receive the therapy, according to a five-year, ... Read more
People with cystic fibrosis (CF) have higher levels of DNA from common microbes that cause CF-related infections circulating in their blood compared to healthy controls, a study discovered. These ... Read more
Problems with the CFTR protein in platelets, blood cells essential to clotting, activated these cells, both driving lung inflammation and injury, and hindering the lungs’ ability to clear bacteria in ... Read more
People with cystic fibrosis (CF) who were treated with Orkambi (lumacaftor/ivacaftor) have significantly less accumulation of fat in the liver — a condition known as hepatic steatosis — which is ... Read more
A triple-antibiotic combination completely eliminated antibiotic-resistant Mycobacterium abscessus, a bacterial infection especially dangerous to people with cystic fibrosis (CF), a study found. Combined doses of three antibiotics — amoxicillin, ... Read more